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Multiple sclerosis (MS) is a chronic and disabling dis-
ease that mostly affects young patients, resulting in huge 
consequences for their physical and cognitive domains, and 
impacting on their quality of life and employability. Its inci-
dence and prevalence is increasing worldwide1 and still no 
definite cause is known, the reason why a straight-line delin-
eation of therapeutic recommendation has been hindered 
and the overall trend has been driven toward a personalized 
and individualized therapeutic rationale.
Throughout the last decade, the number of disease-modi-
fying therapies (DMTs) approved for the treatment of MS has 
increased from just a few to more than a dozen. In addition, a 
number of therapies are often used off-label and several inves-
tigational drugs are going through the later stages of develop-
ment and may soon be approved. While this represents an 
unprecedented opportunity for personalized therapy in MS, 
the choice of DMTs is becoming increasingly complex.
Many aspects of the management of MS have not yet been 
formally assessed by clinical trials. Remarkably, there are few 
head-to-head comparisons between DMTs, few trials in pro-
gressive MS, and no direct comparison between the thera-
peutic strategies known as escalation (starting with safer but 
less efficacious drugs, and escalating to more efficacious and 
often riskier drugs, as needed) and induction (starting with 
highly efficacious “aggressive” treatments in order to prevent 
irreversible accumulation of disability, yet with some seri-
ous adverse effects)2. Nevertheless, these are key aspects and 
must be addressed by guidelines, even if optimal evidence is 
not available.
The treatment of MS in Brazil is largely limited by the 
Ministry of Health Clinical Protocols and Therapeutic 
Guidelines (Protocolos Clínicos e Diretrizes Terapêuticas)3, 
since most patients get their DMTs from the public health 
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RESUMO
O crescent arsenal terapêutico na esclerose múltipla (EM) tem permitido tratamentos mais efetivos e personalizados, mas a escolha e o 
manejo das terapias modificadoras da doença (TMDs) tem se tornado cada vez mais complexos. Neste contexto, especialistas do Comitê 
Brasileiro de Tratamento e Pesquisa em Esclerose Múltipla e do Departamento Científico de Neuroimunologia da Academia Brasileira 
de Neurologia reuniram-se para estabelecer este Consenso Brasileiro para o Tratamento da EM, baseados no entendimento de que 
neurologistas devem ter a possibilidade de prescrever TMDs para EM de acordo com o que é melhor para cada paciente, com base em 
evidências e práticas atualizadas. Por meio deste documento, propomos recomendações práticas para o tratamento da EM, com foco 
principal na escolha e no manejo das TMDs, e revisamos os argumentos que embasam as estratégias de tratamento na EM. 
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system. The current Clinical Protocols and Therapeutic 
Guidelines determine a one-size-fits-all strategy, with mini-
mal flexibility to tailor therapy to the needs and preferences 
of individual patients. Moreover, it delays access to DMTs 
of higher efficacy and fails to include some of the locally-
approved DMTs.
In this context, experts from the Brazilian Committee 
on Treatment and Research in Multiple Sclerosis and the 
Neuroimmunology Scientific Department of the Brazilian 
Academy of Neurology have convened to establish this 
Brazilian Consensus for the Treatment of MS, based on an 
understanding that neurologists should be able to prescribe 
MS DMTs according to what is better for each patient, and 
based on up-to-date evidence and practice. 
METHODS
This guideline represents a consensus of Brazilian experts 
on the management of MS. A panel of 35 representatives 
from the Brazilian Committee on Treatment and Research in 
Multiple Sclerosis and the Brazilian Academy of Neurology 
met on June 6th, 2016. A preliminary version of the proposed 
protocol, previously drafted by two representatives ( JB and 
VDM), was discussed point-by-point by the panel members 
and modified as needed until consensus was reached.
Disease-modifying therapies were considered for inclu-
sion in the protocol if at least one phase 3 trial demonstrated 
their efficacy in MS, plus they were approved by at least one 
of three regulatory bodies: the Brazilian Health Regulatory 
Agency (Agência Nacional de Vigilância Sanitária, ANVISA); 
the United States Food and Drug Administration (FDA); or 
the European Medicines Agency (EMA). Also considered 
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for inclusion were DMTs for which a positive phase 2 or 3 
trial was available, yet without approval for MS by the afore-
mentioned regulatory agencies, but only in the case of them 
already being available or approved for another indication 
in Brazil, in order to maximize the utilization of locally-
available resources. Previous national recommendations 
published by the Brazilian Committee on Treatment and 
Research in Multiple Sclerosis4,5,6,7 and the Brazilian Academy 
of Neurology8,9 were taken into account, as were some key 
international guidelines10,11,2.
On June 23rd, 2016, the panel-approved protocol was pre-
sented at the 17th Brazilian Committee on Treatment and 
Research in Multiple Sclerosis Annual Meeting, the largest 
Brazilian conference on MS, where it was endorsed by the 
attendees. Subsequent minor changes were made due to new 
information that became available during manuscript prepa-
ration. The completed manuscript was subsequently circu-
lated among all panel members for final approval.
DISEASE-RELATED CONCEPTS
The diagnosis of MS must be made according to the 
McDonald criteria, revised in 201713. The clinical course must 
be defined according to the classification of Lublin, modi-
fied in 2013, which includes four phenotypes: clinically iso-
lated syndrome (CIS), relapsing-remitting MS (RRMS), sec-
ondary progressive MS (SPMS), and primary progressive MS 
(PPMS)14. The relapsing-remitting and progressive forms may 
be further stratified by the presence or absence of disease 
activity, which can be defined as the occurrence of clinical 
relapses and/or detection of radiological findings (gadolin-
ium-enhancing lesions and/or new or enlarging T2-weighted 
lesions) on follow-up magnetic resonance imaging (MRI)14. 
The progressive phenotypes may be further categorized 
according to the presence or absence of ongoing progression, 
which can be assessed by clinical measurements of disability, 
at least once annually14. 
In order to guide treatment decisions, some additional 
stratifications are needed: CIS must be classified according 
to the risk of evolving to MS, and disease activity, when pres-
ent, must be classified according to its level, even though 
universally-accepted criteria are lacking. For the purpose of 
this protocol, we define high-risk CIS as any case wherein 
one or more typical T2 lesion(s) on MRI is seen, provided 
both the clinical presentation and MRI lesion(s) are sugges-
tive of central nervous system (CNS) demyelination and not 
attributable to other diseases. For such patients, the risk of 
developing MS ranges from 48% to 81%, depending on the 
number of lesions15. 
Therapeutic decisions in MS are often based on the 
degree of disease activity, which can be rated as low, mod-
erate (or average), and high. The definition of highly active 
MS is still debatable, but we herein adopt this definition: 
1) two or more disabling relapses with incomplete resolu-
tion and at least one gadolinium-enhancing lesion or signif-
icant increase in T2 lesion load in the previous year in treat-
ment-naive patients and 2) breakthrough disease activity in 
the previous year, under an adequate course of at least one 
DMT (in the absence of intolerance or nonadherence), pre-
senting with at least one relapse in the previous year while 
on therapy and at least nine T2 hyperintense lesions or at 
least one gadolinium-enhancing lesion16,17. For the purpose 
of this consensus, whenever disease activity is present but 
does not fulfill the criteria for high activity, it is considered 
as low or moderate activity. 
Aggressive disease can be defined as RRMS with one or 
more of the following features: 1) Expanded Disability Status 
Scale score of 4 reached within five years of onset, or early 
and unexpected acquisition of disability followed by frequent 
relapses; 2) two or more relapses with incomplete resolution 
in the past year; 3) two or more MRI studies showing new or 
enlarging T2 lesions or gadolinium-enhancing lesions despite 
treatment; 4) no response to therapy with one or more DMTs 
for up to one year18,19.
Nonetheless, the above definitions of high activity and 
aggressive disease lack the sensitivity to detect many cases 
with poor prognosis early enough in the disease course. 
However, there are now known to be several clinical and 
radiological factors associated with a poorer prognosis 
(Table 1), which may be present from the onset or become 
apparent during follow-up and suggest evolution to a more 
“aggressive” form of the disease18. Since there is a clear rela-
tionship between the amount of disease activity and final 
prognosis (presented later in the text), we recommend the 
parameters of disease activity should always be analyzed 
alongside the elements concerning prognosis. 
The panel understands that these factors (especially if 
present in association) should prompt the treating neurol-
ogist to consider disease activity as high and the prognosis 
as poor, and to manage DMTs accordingly, even before the 
patient effectively meets the definition for “aggressive” MS. 
This approach may allow for the early optimization of DMTs 
before irreversible accumulation of disability is established.
TREATMENT-RELATED CONCEPTS
This rationale is based on what has been learned over the 
years from observational studies, controlled clinical trials, 
pathophysiological concepts and, more recently, real-world 
registries. In this context, treatment algorithms from many 
countries11,20,21,22,23,24,25,26,27,28,29,30,31 have been guided by what 
have turned out to be very important concepts: 1) early and 
effective treatment; 2) the existence of a therapeutic window 
of opportunity; 3) early optimization of treatment during the 
therapeutic window; 4) the existence of different clinical and 
radiological phenotypes; and 5) treatment decisions based 
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on different levels of inflammatory activity and/or specific 
clinical phenotypes, wherever possible, always favoring the 
best efficacy/risk ratio.
It is widely accepted that the main aspect to be avoided 
or minimized in MS is the accumulation and progression 
of disability, with this representing the central goal in plan-
ning therapeutic decisions. However, the immediate ther-
apeutic effect of current DMTs is, in fact, centered upon 
the prevention of clinical and radiologic activity outbreaks, 
with these being related to focal inflammation. The accu-
mulated disability in MS follows a two-step process. The 
first phase is very dependent on focal inflammation due to 
the impairment of adaptive peripheral immunity, predom-
inating in the initial phase of the disease, and leads to the 
relapsing-remitting phase in which early epitope spread-
ing occurs and underlies the early pathogenic events32,33,34. 
This tends to decline over time as other pathogenic mech-
anisms, mostly related to innate immunity, lead to the 
second phase of the disease, which is not as dependent 
on focal inflammation35, but rather on other more spread 
mechanisms, like CNS-compartmentalized inflammation 
inside lymphoid follicles within the meninges36,37, underly-
ing the progressive phase38. The first stage is characterized 
by the occurrence of clinical relapses and new/enlarg-
ing or gadolinium-enhancing lesions on MRI, due to focal 
demyelinating inflammatory lesions in the early stages of 
the disease, while the second stage is characterized by the 
progressive and sustained worsening of functional capac-
ity by mechanisms of axonal degeneration and brain atro-
phy, which although probably present since the beginning, 
are more evident in the later stages of the disease or in the 
so-called secondary progressive phase. 
There is much evidence relating the degree of inflamma-
tory activity in the first phase of the disease to the disabil-
ity grade achieved in the second phase. Large observational 
cohorts have demonstrated that frequent relapses39 in the 
early years of disease40,41, as well as short intervals between 
relapses40,42,43, are predictors of reaching greater levels of dis-
ability in shorter time periods, while the number of relapses 
after five years of disease does not substantially influence 
the time to achieve levels of permanent incapacity or the 
degree of severity of this phase40. In other words, the early 
course influences long-term evolution. Relapses with resid-
ual sequelae also contribute to the long-term accumula-
tion of disability43,44,45,46,47. This means that irreversible axonal 
degeneration occurs very early and is, at least partly, related 
to inflammation2,48. It has also been observed that an older 
age at disease onset is related to increased risk of a rapid shift 
to a secondary progressive course47,49,50,51,52,53, probably due to 
the progressive decline with aging of the functional reserves, 
neuroplasticity and recovery mechanisms, including remye-
lination. The lesion load on MRI54,55,56,57,58, as well as evidence 
of cerebral atrophy59,60,61,62,63, also have direct correlation with 
long-term disability, meaning that inflammation leads to 
irreversible nervous damage. 
All these data together strongly suggest the existence 
of a therapeutic window, a time in the early stages of the 
inflammatory phase of MS during which therapeutic 
intervention can substantially influence the timing and 
condition in which the patient will reach the progres-
sive stage. The era of monoclonal antibodies came in to 
consolidate the existence of a therapeutic window. A ret-
rospective analysis of controlled clinical trials of alem-
tuzumab revealed that patients treated earlier in the evo-
lution of the disease with a drug considered to have high 
Table 1. Features associated with a poorer prognosis in MS.
Demographic features
Male sex
Age > 40 years at onset
African American or African Latin-American ethnicity
Clinical features
Severe relapse(s) (i.e., associated with ≥ 1-point change on EDSS, ≥2-point change on any individual functional system, or ≥ 1-point 
change on any two functional systems during the acute phase; or requiring steroids or other acute-phase treatments; or requiring 
hospitalization)
Multifocal relapse(s), especially if affecting motor, cerebellar, sphincteric, or cognitive functions
Disabling relapses (i.e., with partial or incomplete recovery)
Frequent relapses in the first 2–5 years after disease onset, or short inter-relapse interval
Rapid accumulation of disability related to relapses, e.g., reaching EDSS score ≥3.0 within five years after disease onset
Radiologic features (MRI)
High disease burden at onset (i.e., high T2 lesion volume, ≥ 2 gadolinium-enhancing lesions; T1 lesions suggestive of “black holes”; 
early signs of brain atrophy; infratentorial and spinal cord lesions)
Evidence of disease activity on follow-up (i.e. new/enlarging T2 lesions and/or gadolinium-enhancing lesions)
Adapted from Rush et al. (2015)18. EDSS: Expanded Disability Status Scale; MRI: magnetic resonance imaging. 
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efficacy showed better results for the parameters of sus-
tained long-term disability, when compared to the group 
receiving treatment later after disease onset64. The find-
ing that disease-modifying drugs can delay the conversion 
from CIS to clinically definite MS65,66,67,68,69,70, together with 
results indicating increased responsiveness to therapies in 
CIS relative to the relapsing-remitting phase, probably due 
to the increasing complexity in pathogenic mechanisms 
as the disease evolves2,32,71, also helps to strengthen the 
concept of a therapeutic window.
The therapeutic window is, therefore, the variable and 
sometimes short time period in which treatment should 
be optimized, linking the need for early treatment with 
that of an effective treatment. Within this context, in addi-
tion to the regular monitoring of radiological and clinical 
disease activity for timely recognition of therapeutic fail-
ure, early definition of the clinical phenotype is of extreme 
importance. Relapses involving the pyramidal, sphincter 
and cerebellar pathways are known to have a higher corre-
lation with the accumulation of disability, when compared 
to relapses involving other neurological fields, such as 
visual and sensory, for instance43,47,49,52,72,73,74. Knowing this 
does not occur randomly, as further relapse phenotypes 
are predicted by the phenotype of previous relapses75,76,77, 
in the vast majority of cases there are elements that are 
predictors of prognosis in a patient’s clinical presenta-
tion (Table 1). The suggestion of there being a differential 
impact of phenotypes on long-term disability can justify, 
wherever possible, an individualized therapeutic man-
agement of different and specific phenotypes. Given the 
different profiles of effectiveness and risk for the various 
drugs currently available, the choice of treatment should 
be carefully considered and based on an individual ben-
efit/risk assessment for the patient, where drug efficacy 
should be appropriate for the severity of phenotype and 
thereby justify or offset the risks.
Changes in the diagnostic criteria for MS, essentially 
aimed at accelerating the diagnostic process, progress in 
neuroimaging techniques in the daily clinical setting, and 
the approval of high-efficacy drugs, has led to expectations 
of greater therapy effectiveness, alongside a trend to toler-
ate less and less disease activity, increasing the possibility 
of enhancing MS treatment remarkably78. The current ther-
apeutic approaches for MS are the so-called escalation or 
induction strategies79.
The rationale for an escalation therapy approach is based 
on initiating treatment as early as possible using the safest 
but also less effective DMT, chosen based on the degree of 
inflammatory activity. This strategy is more often applied 
to mild or moderate clinical phenotypes, and close moni-
toring of clinical and MRI activity is advised. Continuing 
treatment while the disease is stable is recommended, as is 
promptly switching to a more effective drug when the ongo-
ing treatment becomes ineffective or only partially effective, 
escalating the efficacy of treatment (but also increasing the 
risk profile as a consequence)21,80.
The rationale for an induction approach arises from the 
observation that a proportion of MS patients with a more 
aggressive phenotype require more aggressive treatment 
from disease onset; very potent drugs are used earlier in this 
type of approach, with more important safety issues regard-
ing autoimmunity and infectious complications than other 
drugs. These drugs have mechanisms of action that usually 
not only provoke long-term immunological remission, but 
also a re-initiation or “reset” of immunological pathways, or 
immune reconstitution81. This could potentially reduce the 
epitope spreading, which occurs earlier in the disease course, 
and the shift in the main site of immune responses from the 
periphery to the CNS compartment, which seems to occur in 
later phases of MS80.   
Evaluation of prognostic factors must be performed 
every time disease activity is assessed or treatment failure is 
declared, and treatment decisions regarding drug efficacy or 
treatment approach must be adjusted accordingly, to follow 
either a strategy of escalation or induction therapy. 
CONSENSUS FOR THE TREATMENT OF MS
Disease-modifying therapy
The choice of a DMT (and the decision to keep it or change 
it throughout follow-up) depends on several factors, includ-
ing phenotype, prognostic factors, activity, progression sta-
tus, severity, comorbidities, safety profile, tolerability, patient 
preference, convenience, cost, and availability. To date, there 
are no established biomarkers to predict the response of indi-
vidual patients to most DMTs.
Table 2 compiles the DMTs included in the protocol and 
summarizes their posology, clinical efficacy parameters in 
each phenotype (based on the results of key clinical trials 
that support their use in MS), and approval status. Figure 1 
summarizes the general recommendations of the Brazilian 
Consensus for the Treatment of MS with regard to when and 
how to switch DMTs in different contexts, such as lack of effi-
cacy or safety concerns. Figure 2 lists the DMTs that have 
been included in the Consensus for different MS phenotypes, 
according to the risk of conversion from CIS to MS, as well as 
the level of disease activity in RRMS and SPMS. 
The first set of DMTs presented for each group in 
Figure 2 represents the most appropriate initial choices. 
In the event of intolerance, poor adhesion and/or serious 
adverse effects, DMTs could be switched within the same 
groups. On the other hand, in the event of therapeutic fail-
ure, patients should be reassessed in relation to phenotype 
and disease activity, and DMTs should be managed accord-
ingly, which may involve switching to higher efficacy drugs. 
For example, upon therapeutic failure, a patient with CIS 
will nearly always have met the criteria for RRMS, and a 
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Choice of DMT
Monitor disease activity (clinically and by MRI) and reassess the phenotype periodically; monitor adherence 
and tolerance to the DMT; implement safety monitoring as recommended in the product label and current literature
If all options within the 
specifc box are exhausted, 
consider switch to DMT 
from the “alternative” box 
(see figure 2)
Switch to DMT from the 
now-appropriate box (see 
figure 2), according to the 
new phenotype and current
level of disease activity
Switch to another 
DMT from the same 
box (see figure 2)
Switch to another 
DMT from the same 
box (see figure 2)
Keep current DMT; or
If desired and appropriate, 
consider switch to 
lower potency DMT
Change in disease 
activity or transition 
to different phenotype
Persistent activity or 
progression, but 
phenotype and level 
of activity unchanged
Intolerable side effects 
or complications
Satisfactory control of 
the disease and 
no issues with the DMT
DMT: disease-modifying therapy; MS: multiple sclerosis.











































*DMTs currently not approved for MS by the Brazilian Health Regulatory Agency (Agência Nacional de Vigilância Sanitária, ANVISA). CIS: clinically isolated syndrome; 
DMT: disease-modifying therapy; MS: multiple sclerosis; PPMS: primary progressive multiple sclerosis; SPMS: secondary progressive multiple sclerosis.
Figure 2. DMTs included in the Brazilian Consensus for the Treatment of MS. The classification of MS guiding the choice of DMT in this 
flowchart is based on the combined assessment of MS phenotype, level of disease activity, and factors of poorer prognosis (if present).
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patient with low disease activity may have evolved to high 
disease activity. Conversely, if the management of highly 
active disease with potent DMTs has achieved a satisfac-
tory response and stability for several years, it would be 
acceptable (though not mandatory) to consider switching 
to a lower potency DMT. Finally, if a patient with relaps-
ing MS fails to achieve satisfactory responses (or presents 
intolerance or safety concerns) with multiple DMTs from 
the first group, a switch to DMTs of the second (alterna-
tive) group shown in Figure 2 should be considered.
CIS
In patients with CIS, the main therapeutic goal is to pre-
vent (or at least delay) the conversion to MS, i.e., the develop-
ment of further clinical relapses or new MRI lesions that may 
lead to fulfillment of the McDonald criteria for RRMS. It is 
likely that all MS DMTs may be effective in doing so; however, 
in many CIS cases there remains some uncertainty regarding 
the likelihood of evolving to MS, thus it seems reasonable to 
start DMTs only in patients with high-risk CIS, as well as to 
choose safer drugs. 
Up to the present time, efficacy in CIS has been dem-
onstrated with the beta interferons, cladribine, glatiramer 
acetate, and teriflunomide65-70,82. Since no direct comparison 
between these is available, any of these drugs are deemed 
appropriate for the treatment of high-risk CIS. 
Relapsing MS
For the purpose of this guideline, we define relapsing MS 
as any case of RRMS, irrespective of disease activity, as well as 
SPMS with persistence of superimposed relapses or radiologic 
signs of activity. This approach reflects the panel’s view that, 
in patients transitioning from the relapsing-remitting form to 
the secondary progressive form, the presence of relapses may 
suggest a residual “relapsing” pathophysiological component, 
potentially treatable with DMTs, which may persist for years. 
This view is further supported by recent clinical trials includ-
ing both RRMS and SPMS with relapses, grouped under the 
term “active relapsing MS”83, as well as the recent approval 
by health authorities of some DMTs for “relapsing forms of 
MS”. The panel recognizes that many of the pivotal trials for 
DMTs have included only RRMS patients, with the efficacy of 
such drugs for SPMS being less clear. On the other hand, it 
also acknowledges that the distinction between RRMS and 
SPMS in clinical practice is often challenging and may take 
months or years until the presence of ongoing disease pro-
gression (and thus SPMS) is clearly established, particularly if 
there remain superimposed relapses.
The main goals in patients with relapsing MS are to 
reduce the annualized relapse rate and appearance of new 
or enlarging MRI lesions, and consequently the accumula-
tion of disability. Identifying those with high disease activ-
ity (or at higher risk of evolving to a more aggressive form of 
the disease) is of paramount importance to guide the choice 
of DMT. 
If there are no particular concerns regarding high lev-
els of disease activity, it would seem reasonable to start 
treatment with interferon beta-1a84,85, interferon beta-
1b86, glatiramer acetate87,88, pegylated interferon beta-1a89, 
dimethyl fumarate90,91, or teriflunomide92,93, which usu-
ally have a good safety profile and are often more easily 
available (including in the Brazilian public health sys-
tem). Overall, these drugs are associated with a moderate 
reduction in the annualized relapse rate in comparison to 
placebo (around 30%; except for dimethyl fumarate with 
an efficacy of around 50%).
For patients meeting the criteria for highly active relaps-
ing MS, or presenting factors associated with poorer progno-
sis, the treating neurologist should consider drugs of higher 
potency (associated with a reduction greater than 50% in 
the annualized relapse rate, usually compared with placebo), 
whose efficacy has been well established by phase 3 trials. 
This group comprises alemtuzumab94,95, cladribine96, fingo-
limod97,98, natalizumab99, and ocrelizumab100. These drugs 
are usually associated with more serious safety concerns, 
including opportunistic infections or secondary autoim-
mune diseases, to cite a few. Nevertheless, the need to con-
trol aggressive (or potentially aggressive) MS before irrevers-
ible disability accumulates often justifies the use of such 
drugs. At the time of the consensus panel meeting, this group 
of drugs also included daclizumab101,102, but it has since been 
withdrawn from the market (and removed from this guide-
line) due to recently detected safety issues103,104.
A subset of highly active relapsing MS patients may per-
sist with breakthrough disease despite treatment with several 
drugs from the high potency group, characterizing refrac-
tory MS. In such cases, subsequent therapy is largely empiric 
and may include DMTs like cyclophosphamide105, intrave-
nous immunoglobulin106, mitoxantrone107, rituximab108, and 
autologous hematopoietic stem cell transplantation109. These 
DMTs have had their efficacy suggested by phase 2 trials only 
(except for mitoxantrone, which was investigated in a phase 
3 trial) and are often associated with serious adverse effects, 
including infertility, neoplasms, or cardiotoxicity). In this 
group, as an alternative to the aforementioned drugs, exper-
imental DMTs may also be considered, as long as they are 
offered in a research setting, under appropriate regulatory 
and ethical approval. 
Non-active SPMS
There remains a lack of substantial evidence supporting 
the benefit of any particular DMT for patients with clearly-
established SPMS that no longer presents relapses. Not pre-
scribing a DMT is an acceptable choice in this group. If a 
DMT is considered (e.g., if there is uncertainty regarding the 
secondary progressive phenotype in a particular case), the 
off-label nature of this approach should be clearly discussed 
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with the patient. In this context, interferon beta-1b could 
be preferred, based on one positive phase 3 trial in SPMS110. 
In cases of rapidly-progressive disease, there is some evi-
dence supporting the use of DMTs such as cyclophospha-
mide, mitoxantrone, and autologous hematopoietic stem 
cell transplantation, but these would also represent off-
label treatments. 
A phase 3 trial of siponimod in patients with SPMS has 
recently been published, showing modest efficacy in reduc-
ing the progression of disability111. However, evaluation and 
approval by health authorities are still pending; therefore, 
siponimod has not been included in this guideline.
PPMS
The current main therapeutic goal in PPMS is to delay 
the progression of disability. The only drug approved for this 
purpose is ocrelizumab, with a modest benefit112. Hence, the 
consensus panel understands that ocrelizumab should be 
the treatment of choice for patients with PPMS, after con-
sideration of the expected benefits and potential risks on a 
case-by-case basis.
Special situations
Pediatric MS: To date, the Food and Drug Administration, 
European Medicines Agency, and Brazilian Health Regulatory 
Agency have not approved most DMTs for patients younger 
than 18 years. This reflects the lack of phase 3 randomized 
clinical trials assessing MS drugs in this age range. Meanwhile, 
the treatment of pediatric MS remains largely off-label, based 
on evidence from observational studies. Beta interferons 
and glatiramer acetate are seemingly safe and effective in 
this population and should be preferred as first-line ther-
apy, at least until growing evidence and regulatory clearance 
becomes available for the newer DMTs113. Attention should 
be paid to the specific dose initiation and titration schemes 
recommended for younger children. Upon therapeutic fail-
ure, escalation to drugs other than beta interferons and glat-
iramer acetate may be considered with caution. Positive 
results of fingolimod in a phase 3 trial in pediatric MS were 
recently reported in a conference114, but publication of the full 
study was still pending during the preparation of this guide-
line and, therefore, the panel could not make a specific rec-
ommendation on whether fingolimod should be preferred 
over other DMTs in this age group.
Pregnancy and breastfeeding: As for pediatric MS, there 
is only scarce evidence guiding the decision on whether or 
not to use DMTs (and how to choose them) during pregnancy 
and breastfeeding. Treating neurologists should discuss this 
on a case-by-case basis and, when the use of a DMT is judged 
necessary, glatiramer acetate should usually be preferred 
over others DMTs.
Radiologically isolated syndrome: At this point, the con-
sensus panel understands there is insufficient evidence to 
recommend the use of DMTs for patients with radiologically 
isolated syndrome, i.e., those with the incidental finding of 
MS-typical lesions on MRI who lack evidence of symptoms 
or signs compatible with MS. 
Tumefactive demyelination syndromes: This is a group of 
heterogeneous conditions whose relationship to MS is still 
to be fully elucidated. The consensus panel recommends that 
only patients fulfilling the diagnostic criteria for MS should 
be eligible for DMTs. At this point, there is insufficient evi-
dence to guide the choice of specific DMTs. Beta interferons 
and glatiramer acetate are the most commonly used drugs 
in most case series, thus could be regarded as preferred115,116. 
On the other hand, there are reports of a controversial asso-
ciation between fingolimod and the occurrence of tumefac-
tive lesions (as well as unfavorable outcomes in this group 
of patients); thus the panel recommends particular caution 
when prescribing this drug to patients with tumefactive 
demyelinating syndromes116,117.
Treatment interruption: There is no clear evidence to sup-
port a consensus recommendation on whether or when to 
consider interruption of DMTs in patients with advanced 
MS or in those with the disputable entity known as “benign 
MS”118. The treating neurologist should discuss this with 
patients and their family on an individual basis. 
For further guidance on the management of special sit-
uations, we refer the reader to the recommendations of the 
Brazilian Academy of Neurology. 
Management of relapses
Figure 3 summarizes the recommendations for the man-
agement of relapses. The initial choice is usually intravenous 
methylprednisolone, 1 g/day, infused over at least 30 minutes, 
for three to five consecutive days119. If intravenous methyl-
prednisolone fails to promote satisfactory recovery, an addi-
tional course may be given, with the same or higher dose 
(1–2 g/day), again for three to five days. High-dose oral meth-
ylprednisolone (1 g/day) or dexamethasone (150 mg/day), for 
three to five consecutive days, may be considered in the out-
patient setting120,121.
Patients who fail to respond (or have contraindications) 
to corticosteroids may be eligible for therapeutic plasma 
exchange (five to seven sessions scheduled every other day) 
or intravenous human immunoglobulin G (usually 1 g/kg/
day for two days, or 0.4 g/kg/day for five days)119. It is noted 
that plasma exchange is likely more effective than intrave-
nous immunoglobulin; however, it is not easily available in 
most centers in Brazil.
Symptomatic treatment and rehabilitation
Although a comprehensive review of symptomatic treat-
ment and rehabilitation is beyond the scope of this guideline, 
the panel acknowledges the paramount importance of such 
aspects in the treatment of MS and highlights the need to pro-
actively consider these resources and offer them to patients 
in need, whenever possible. We recommend accessing the 
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Brazilian Academy of Neurology recommendations to review 
these treatments. 
Symptoms and disability in the context of MS, such as 
neurogenic bladder and bowel dysfunction, neuropsycholog-
ical conditions, sleep disorders, neuropathic pain and spas-
ticity, are usually managed similarly as in the context of other 
neurological conditions. Nonetheless, it is worth bearing in 
mind that some MS-specific symptomatic drugs are avail-
able, namely tetrahydrocannabinol + cannabidiol for refrac-
tory spasticity and fampridine for gait dysfunction122. 
Vitamin D3 supplementation
Vitamin  D3 (cholecalciferol)  is a fat-soluble hor-
mone with  numerous physiologic responses, including 
immune  regulation123. Preliminary  studies of vitamin D3 
as an add-on therapy in MS have shown promising results, 
but none have yet provided significant evidence  of a clini-
cally meaningful effect on disease activity. Until the  results 
of ongoing larger randomized controlled trials help elucidate 
the role of vitamin D supplementation in MS, the panel rec-
ommends to check the serum level of 25-OH-vitamin D3 in 
all patients with MS, and to consider supplementation on 
a case-by-case basis, in physiologic doses, i.e., sufficient  to 
achieve serum  levels between 40 and 100 ng/mL  (100–150 
nmol/L)124. After starting supplementation, serum levels 
should be re-checked after three  months, to further tailor 
the dose, as MS patients may have a less  robust response 
to supplementation compared to those without comorbidi-
ties123. The panel herein emphasizes that supraphysiological 
doses of vitamin D3, i.e., those leading to a serum level higher 
than 100 ng/mL, are not indicated, neither as an add-on nor 
as monotherapy in MS, due to potential systemic toxicity124. 
FINAL REMARKS
This guideline provides an overview of the principles and 
general directions that should guide therapeutic decisions 
in MS. Overall, we highlight the need to start DMTs early in 
the course of MS, always conforming properly to the clinical 
phenotype, and changing them promptly in the case of treat-
ment failure to prevent further relapses and accumulation 
of disability. We advocate for flexibility in the management 
of DMTs, so it can be tailored to individual circumstances 
(especially disease activity), rather than adhering to a rigid 
sequence of treatment lines. 
We acknowledge that these recommendations are unable 
to cover all the situations that neurologists may face in the 
management of MS. Furthermore, the need for periodic revi-
sions is anticipated, as further understanding of the dis-
ease and new medications become more rapidly available. 
Therefore, we encourage treating physicians to always review 
additional information (especially from each drug’s label), and 
to examine all the relevant factors on a case-by-case basis.
RELAPSE





Additional course of 
intravenous 
methylprednisolone 
(1-2 g/day, 3-5 days)
Plasma exchange (5-7 sessions); or
Intravenous immunoglobulin (2g/kg, divided 




(1 g/day, 3-5 days)
Mild Moderate or severe
Intravenous 
methylprednisolone 
(1 g/day, 3-5 days)
or
MS: multiple sclerosis.
Figure 3. General strategies for the management of MS relapses.
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